Kornimate/medical-research-clean huggingface dataset:
fit (fast infarction treatment): complete revascularization during primary percutaneous coronary intervention (pci) can be achieved safely with an improved clinical outcome during the indexed hospitalization.

Conditions: Myocardial Infarction; Ischemia; Heart Failure; Necrosis; Stents

Summary: few reports described outcomes of complete compared with infarct related artery (ira) only revascularization in patients with st elevation myocardial infarction (stemi) and multivessel coronary disease (cad). the purpose of this study is to determine outcome (death, myocardial infarction, target vessel failure) of 180 consecutive patients with stemi and multivessel cad undergoing primary angioplasty. before the first angioplasty patients are randomized to 2 different strategies: 1) culprit vessel angioplasty only, 2) staged revascularization.


Eligibility criteria:
inclusion criteria: * myocardial acute infarction * prolonged chest pain (\>20 minute) started less \<12 hours before arrive in hospital * st segment elevation of \>1mm in \>2 contiguous leads * new left bundle branch block * diameter of the coronary suitable of angioplasty \>2mm * the patients agrees to the study protocol and provides a written consensus * two or more coronary suitable for angioplasty exclusion criteria: * refused written consensus * hypersensitivity or contraindication to any of the following medications: heparin bivalirudin aspirin prasugrel stainless steel * history of bleeding * cardiogenic shock (pa \< 90mmhg) * chronic total occlusion in the second lesion * timi flow \< ii in the culprit lesion * recent pregnancy * history of intra-cerebral major hemorrhagic stroke * an elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment life expectancy \<1 year

Keywords: cardiovascular diseases heart disease hemorrhage coronary angioplasty drug eluting stents
virtual training for latino caregivers to manage symptoms of dementia

Conditions: Caregiver Burden; Alzheimer Disease; Dementia; Behavioral Symptoms

Summary: the goal of this pilot study is to improve the star-caregivers virtual training \& follow-up (star-vtf) intervention for latino caregivers of people living with dementia. the main objectives are to: (1) culturally adapt star-vtf online training modules, (2) pilot test latino caregivers' responses to the adapted online training modules, and (3) develop an online survey to collect caregiver outcomes in a future study. participants will receive the star-vtf intervention and asked to complete online surveys and participate in an exit interview to provide feedback on their experience.

the objectives of this study are to: (1) culturally and linguistically adapt the star-caregivers virtual training \& follow-up (star-vtf) online training modules for latino caregivers of people living with dementia (plwd), (2) pilot test latino caregivers' responses to the adapted online training modules, and (3) develop a redcap survey to pragmatically collect caregiver outcomes in a future study. the study will use a single-arm pilot trial design with latino caregivers of plwd. the investigators will assess self-reported outcomes at baseline and 6-8 weeks post-enrollment using a redcap survey. outcome measures will include the revised memory and problem behavior checklist and preparedness for caregiving scale. in addition, the investigators will assess caregivers' perceived usability of the online training modules and will conduct qualitative interviews 6-8 weeks post-enrollment. the interviews will assess caregiver satisfaction with and acceptability of the adapted online training modules. the investigators expect to enroll up to 20 participants. the primary objective of this study is to pilot test the adapted online training modules. therefore, it is not powered to detect an effect of the intervention.

Eligibility criteria:
inclusion criteria: * age 18 years or older * lives with a person living with dementia (plwd) or within 5 miles * provides at least 8 hours of care per week * self-identifies as hispanic/latino * caregiver self-report of plwd having ≥ 3 behavioral and/or psychological symptoms of dementia occurring ≥ 3 in past week exclusion criterion: * plwd lives in assisted living or skilled nursing facilities
inhaled loxapine vs intramuscular (im) haloperidol + lorazepam for agitation

Conditions: Agitation,Psychomotor; Haloperidol Causing Adverse Effects in Therapeutic Use; Lorazepam Causing Adverse Effects in Therapeutic Use; Loxapine Causing Adverse Effects in Therapeutic Use

Summary: the primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

the primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

Eligibility criteria:
inclusion criteria: 1. requires treatment for agitation in the judgment of a physician 2. patient either pre-consented, has surrogate consent, or able to consent (in cases of mild agitation). 3. the patient is at least 18 years of age and less than 65 years of age. 4. patients with known or presumed schizophrenia or bipolar 1 disorder. exclusion criteria: 1. patients with acute respiratory signs/symptoms (eg, wheezing). 2. known diagnosis of chronic obstructive pulmonary disease (copd) or asthma or taking meds for asthma or copd. 3. female patients who are obviously pregnant or breast-feeding. 4. medically unstable patients. 5. patients or surrogates who object to being in the study (even if previously pre-consented). 6. physician objection to patient enrollment in the study. 7. prisoners or incarcerated.
distribution of biospecimens from biorepositories/biobanks for research use

Conditions: Cancer; Pregnancy Related; Gastro-Intestinal Disorder; Cardio-Respiratory Distress; Women's Health: Endometriosis; Autoimmune Diseases; Nephritis; Healthy; Neuro-Degenerative Disease

Summary: this protocol seeks to assist biorepositories/biobanks in distributing their stored specimens and data to researchers that will actually utilize them to advance medicine and technology.

ispecimen has built a partner network comprised of supplying institutions that have ethically acquired human biospecimens and created biorepositories/biobanks to store the specimens and data. many of these biorepositories have protocols allowing for the collection of their samples but require an additional irb or ethics review for the distribution of their samples. this protocol establishes a method of such supply sites to allow their specimens to be distributed and used for research via ispecimen's technology and network of research clients.

Eligibility criteria:
inclusion criteria: * specimens and/or data from biorepositories that have enrolled subjects that have provided consent for the specimens and de-identified data to be collected, stored and distributed. * specimens from biobanks that have collected materials and de-identified data under a waiver of consent * specimens from a biobank that meet the criteria for non human subject research under the common rule. exclusion criteria: * specimens and/or that have been obtained from subjects without informed consent, nor waiver of consent or that do not meet the criteria for non human subject research under the common rule.

Keywords: observational
study of relationship between ugt1a1 gene polymorphism and toxicity and efficacy of irinotecan in small cell lung cancer

Conditions: Small Cell Carcinoma of Lung

Summary: the purpose of this study is to find out the correlation between uridine diphosphate glucuronosyl transferase 1a1(ugt1a1) gene polymorphisms and the side effect and efficacy of irinotecan in patients with small cell lung cancer.

in multiple studies of metastatic colorectal cancer,uridine diphosphate glucuronosyl transferase 1a1(ugt1a1) gene polymorphisms and its correlation with irinotecan-associated side effects have been confirmed.data from several studies indicated an improved clinical outcome of patients who had received an irinotecan-based regimen.in order to find out the correlation between ugt1a1 gene polymorphisms and the side effect and efficacy of irinotecan in patients with small cell lung cancer,we designed this study.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of refractory or relapsed small cell lung cancer * physical examination and routine laboratory tests show no contraindications to chemotherapy exclusion criteria: * pregnant and nursing women * brain metastasis with symptoms

Keywords: irinotecan ugt1a1 gene polymorphisms small cell carcinoma of lung
emotion focused family therapy for parents of children with mental health difficulties

Conditions: Anxiety; Depression; Behavior Problem

Summary: emotion focused family therapy (efft) is a promising intervention that aims to teach parents advanced skills to support their child's development of emotion skills and increase their adaptive behaviours, potentially leading to improvements in their child's psychological functioning and family functioning more broadly. this randomized controlled trial (rct; efft vs waitlist control) will (1) test the efficacy of a 6-week group efft program on parent and child outcomes and (2) examine maintenance of treatment gains up to four months post-intervention.

this randomized controlled trial (rct) will test the efficacy of a 6-week emotion focused family therapy (efft) group program on parent and child outcomes, compared to a waitlist control. families will be randomized to either the efft group treatment or a waitlist. the rct will evaluate changes in parent functioning, child functioning, and parent-child relationship functioning. a 4-month follow-up will test whether any changes from pre-to-post intervention are maintained at 4 months. the rct will also test proposed mechanisms of change (parent-child relationship quality, family functioning) and moderators of treatment effectiveness (parental stress).

Eligibility criteria:
inclusion criteria: * parent of child aged 7 to 15 years old with anxiety, depression, or behavioural challenges * parent of child is willing to participate in intervention * parent is living at home with the child exclusion criteria: * parent or child not proficient enough in speaking/understanding english to complete measures or efft intervention components * parent or child with a severe mental health disorder (e.g., active suicidality and psychosis) is not considered suitable for the trial intervention due to the clinical need for immediate intervention * parent or child is actively receiving, or due to receive, intensive psychological intervention focused on cognitive and/or behavioural strategies to intervene with emotional or behavioural difficulties * parent or child has any disabilities in language, speech or hearing that would interfere with their completion of the efft and measures * parent or child are allergic to adhesive electrode gel use in some tasks (i.e., sodium chloride)

Keywords: children parents mental health emotion psychotherapy parent-child relationship
driving performance of people with parkinson's using autonomous in-vehicle technologies

Conditions: Parkinson Disease

Summary: for drivers with parkinson's disease (pd), autonomous in-vehicle technologies may help mitigate functional deficits, improve driving performance, decrease driving errors and enhance their ability to stay on the road. using a pretest/posttest design the investigators will quantify the use of in-vehicle information systems (ivis) and advanced driver assistance systems (adas) during driving to illustrate how ivis and adas may affect driving, and provide recommendations to drivers with pd, the clinical community and industry.


Eligibility criteria:
inclusion criteria: 1. subjects diagnosed by a neurologist/ movement disorder specialist with clinically probable pd by movement disorders society (mds) criteria 25 2. has mild or moderate disease severity, based on the mds-unified parkinson's disease rating scale for motor symptoms (hereafter referred to as the updrs section 3) in the on state of medications (i.e., one hour of taking pd medications) and the modified hoehn and yahr disease severity scale 3. is representative of one of two pd groups based on age, i.e., participants with symptom onset between 35-64 years of age (younger onset), or participants with symptom onset between ages 65- 85 years (older onset) 4. currently driving with a valid license 5. meets the florida state requirement for visual acuity of at least 20/50 in one eye, if one eye is blind or 20/200 or worse the other eye must be 20/40 or better (20/40 in at least one eye) and field of vision (130 degrees or more) 6. lives independently in the community 7. proficient in reading/speaking english 8. a montreal cognitive assessment (moca) score of 20 or higher exclusion criteria: 1. concurrent neurological conditions (e.g., stroke, seizures; dementia) 2. severe psychiatric (e.g., psychoses/ significant anxiety) or physical conditions (e.g., missing limbs) precluding full participation 3. use of psychotropic medications having adverse effect on mental/physical functioning 4. severe, unpredictable motor fluctuations 5. severe sleep difficulties.

Keywords: parkinson disease in-vehicle information system advanced driver assistance system
clinical evaluation of the click sexual health test for the detection of neisseria gonorrhoeae (ng), trichomonas vaginalis (tv), and chlamydia trachomatis (ct) in women

Conditions: Chlamydial Infection; Gonococcal Infection; Trichomoniasis

Summary: this study is a multi-center study with a minimum of three clia-waived intended operator sites in the united states in which prospectively self-collected vaginal specimens obtained from subjects who are symptomatic or asymptomatic for ct, ng, or tv will be evaluated with the click sexual health test in a clinical laboratory improvement amendments (clia) waived setting. subjects interested in participating in this study will be assessed for eligibility and asked to give informed consent and assent, if applicable, by the investigational review board (irb). only those subjects who meet the inclusion and exclusion criteria may be enrolled in the study.


Eligibility criteria:
inclusion criteria: 1. willing and able to give voluntary written informed consent and assent form (or the parental/legal guardian will provide parental permission) before any study-related procedure is performed. 2. female at birth. (pregnant and breastfeeding women are eligible). 3. age greater than or equal to 14 years at the time of enrollment 4. able to read and understand the procedural information provided for the study. 5. able and willing to follow all study procedures, including performing self-collection of one vaginal swab and permitting a hcp to collect three additional vaginal swabs. exclusion criteria: 1. have a medical condition, serious intercurrent illness, or other circumstance that, in the investigator's judgement, could jeopardize the subjects's safety, or could interfere with study procedures. 2. enrollment in the dmid 18-0024 and this study previously. 3. use of antiperspirants and deodorants or the following vaginal products: douches, washes, lubricants, vaginal wipes, vaginal moisturizers, or feminine hygiene spray in the genital area, within 48 hours prior to enrollment.
autologous bronchial basal cells transplantation for treatment of crd including copd, be and pf

Conditions: Chronic Respiratory Disease

Summary: chronic respiratory diseases including chronic obstructive pulmonary disease (copd), bronchiectasis (be) or pulmonary fibrosis (pf) are usually not curable with damaged pulmonary structure and function. bronchial basal cells are proved to regenerate bronchus and alveoli to repair the pulmonary injuries. in this study, we intend to perform an open, single-armed phase i clinical trial by transplantation of autologous bronchial basal cells on patients suffered from copd, be or pf. during the treatment, autologous bronchial basal cells, which were isolated from fiberoptic bronchoscopy and expanded in vitro, will be injected directly into lesions by fiberoptic bronchoscopy after careful characterization. in the following 6 months, the safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.


Eligibility criteria:
inclusion criteria: * diagnosed with copd, be or pf according to the guideline; * clinically stable for more than 4 weeks; * tolerant to fiberoptic bronchoscopy test; * written informed consent signed. exclusion criteria: * pregnant or lactating women; * patients positive for syphilis, hiv; * patients with malignant tumor; * patients with serious significant pulmonary infection and need anti-infection treatment; * patients with serious heart disease(nyha class ⅲ-ⅳ); * patients with a history of abusing alcohol and illicit drug; * patients participated in other clinical trials in the past 3 months; * patients assessed as inappropriate to participate in this clinical trial by investigators.
pilot study of ultrasound in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: little is currently known as to the predictive value of ultrasound in guiding the decision to taper drug treatment in patients with stable rheumatoid arthritis, nor the influence that patients' views and opinions regarding their medications may have upon this. in this study, patients with stable rheumatoid arthritis will undergo a simple examination of their joints to look for any swelling or tenderness followed by an ultrasound scan to look for joint inflammation. half of the patients will also complete an interview to assess their views and opinions of arthritis drug treatment. the study will be completed in a single patient visit - no invasive tests will be performed, and no changes to treatment will be made. this study is being conducted as part of a masters degree from newcastle university. the results of this study will be used to inform the feasibility of inclusion of ultrasound assessment within the design of a future phd study to investigate potential markers of remission in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis with symptom onset at least 12 months previously * current disease-modifying anti-rheumatic drug (dmard) therapy or biologic therapy * currently stable arthritis defined as no change in dmard treatment over previous 6 months, and no use of steroids (enteral, parenteral or intra-articular) over previous 6 months exclusion criteria: * inability to provide informed consent * current or recent (within 4 months) participation within another clinical trial

Keywords: rheumatoid arthritis ultrasound remission qualitative
functional training to improve everyday performance in elderlies

Conditions: Back Pain, Low; Knee Pain Chronic; Hip Pain Chronic

Summary: to investigate how elderlies (+65 years old) everyday movements, general strength and dynamic balance are affected after an 8-12-week training period using the "ssa elderly performance system" or "strong and steady".


Eligibility criteria:
inclusion criteria: * elderlies aged 65 to 75 years old. * have been participating and physical training for at least six months before the start of the intervention. * the participants must be highly motivated for the project, which will be measured using the likard scale. exclusion criteria: * illness or injury within the last three months. * do not have the ability to complete the test battery concerning set minimum criteria
comparison of conventional and large diameter femoral heads for the prevention of hip dislocation

Conditions: Hip Dislocation

Summary: about ten percent of revision hip replacements will dislocate. although dislocation is not a life-threatening problem, it is stressful and costly and requires hospitalization to treat. subjects who have repeated dislocations live with the constant fear of another dislocation. the purpose of this study is to test the effectiveness of a large ball prosthesis in preventing post-surgical dislocation. a large diameter ball has greater freedom of movement before it impinges; therefore, theoretically, it should not dislocate as easily.


Eligibility criteria:
inclusion criteria: 1. eligible patients will be those undergoing revision hip arthroplasty, either first revision or subsequent re-revision. 2. revision must require replacement of both the acetabular component and femoral component, except when revising femur only with well-fixed trilogy socket. 3. the acetabular component must have a minimum outer diameter of 50 mm. 4. the femoral component inserted should be a zimmer versys™ beaded full-coated stem or zimmer zmr™ stem or collarless polished taper (cpt™) 5. patients must be able to reply to questionnaires in either french or english. exclusion criteria: 1. patients who are undergoing revision for recurrent dislocation. 2. revision of the acetabulum requiring structural allograft or reconstruction ring. 3. revision of the acetabulum requiring the use of cemented all-polyethylene cups. 4. revision of the acetabulum using a liner cemented into an existing metal shell. 5. intra-operative decision to use a constrained liner.

Keywords: post-arthroplasty hip dislocation